Fust Matthew K — SEC Form 4 filings
SEC reporting owner CIK 1397266. 18 Form 4 filings on record with FilingPulse; latest filed 2026-09-01.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-03-11 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 4 filings — 109,983 shares, $4,355,555 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 58.
- Largest priced transaction: sale of 17,500 shares @ $45.50 ($796,250) in Crinetics Pharmaceuticals, Inc., filed 2024-03-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) | Director | 6 | — | 5 legs · 76,000 sh · $3,364,150 | 23 |
| Ultragenyx Pharmaceutical Inc. (RARE) | Director | 4 | — | 3 legs · 12,195 sh · $620,443 | 6 |
| Neumora Therapeutics, Inc. (NMRA) | Director | 5 | — | 2 legs · 21,788 sh · $370,962 | 26 |
| Atara Biotherapeutics, Inc. (ATRA) | Director | 3 | — | — | 3 |
Form 4 filings — Fust Matthew K
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Disposition to issuer (D): 22,836 @ $85 · Disposition to issuer (D): 5,925 @ $85 · Disposition to issuer (D): 2,092 (derivative) @ $83.09 · Disposition to issuer (D): 17,500 (derivative) @ $64.68 · Disposition to issuer (D): 12,500 (derivative) @ $40.29 · Disposition to issuer (D): 10,350 (derivative) @ $52.67 · +1 more | EDGAR |
| 2026-06-22 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2026-05-29 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Option exercise (M): 10,000 @ $1.91 · Sale (S): 16,000 @ $44.75 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 7,828 @ $0 | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 85,586 (derivative) · Disposition to issuer (D): 27,802 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 85,586 (derivative) · Grant/award (A): 27,802 (derivative) · Grant/award (A): 28,571 (derivative) · +1 more | EDGAR |
| 2025-05-19 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 85,586 (derivative) · Disposition to issuer (D): 27,802 (derivative) · Disposition to issuer (D): 28,571 (derivative) · Grant/award (A): 85,586 (derivative) · Grant/award (A): 27,802 (derivative) · Grant/award (A): 28,571 (derivative) | EDGAR |
| 2024-10-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Option exercise (M): 3,783 @ $8.32 · Option exercise (M): 1,800 @ $8.79 · Option exercise (M): 2,156 @ $2.52 · Sale (S): 7,739 @ $17.01 · Option exercise (M): 6,205 @ $8.79 · Option exercise (M): 7,844 @ $2.52 · +6 more | EDGAR |
| 2024-06-20 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 5,345 @ $0 · Grant/award (A): 9,900 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 20,100 @ $0 · Grant/award (A): 28,571 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 3,400 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2024-03-22 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Option exercise (M): 12,500 @ $23.24 · Sale (S): 12,500 @ $43.57 · Option exercise (M): 12,500 @ $23.23 · Sale (S): 12,500 @ $43.57 · Option exercise (M): 17,500 @ $20.23 · Sale (S): 17,500 @ $43.58 · +6 more | EDGAR |
| 2024-03-11 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 2,550 @ $50.89 · Sale (S): 2,145 @ $50.85 · Sale (S): 7,500 @ $50.88 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1397266 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →